Peter M Ravdin

Summary

Publications

  1. ncbi request reprint Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables
    Peter M Ravdin
    Division of Medical Oncology, University of Texas Health Sciences Center at San Antonio, USA
    Lung Cancer 52:207-12. 2006
  2. doi request reprint Hormone replacement therapy and the increase in the incidence of invasive lobular cancer
    Peter M Ravdin
    University of Texas Health Sciences Center, San Antonio, TX, USA
    Breast Dis 30:3-8. 2008
  3. ncbi request reprint A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen
    Peter M Ravdin
    Division of Oncology, University of Texas Health Sciences Center, San Antonio, USA
    Clin Breast Cancer 5:313-6. 2004
  4. ncbi request reprint Managing the risk of osteoporosis in women with a history of early breast cancer
    Peter M Ravdin
    University of Texas Health Science Center San Antonio, Texas 78259 2307, USA
    Oncology (Williston Park) 18:1385-90, 1393; discussion 1394. 2004
  5. doi request reprint The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention
    Peter M Ravdin
    University of Texas Health Sciences Center at San Antonio, 78229, USA
    Cancer Prev Res (Phila) 3:686-8. 2010
  6. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
  7. ncbi request reprint A decision aid to assist in adjuvant therapy choices for breast cancer
    Laura A Siminoff
    Case Western Reserve University, Cleveland, OH 44106 4976, USA
    Psychooncology 15:1001-13. 2006
  8. ncbi request reprint Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information
    Pamela B Peele
    Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA
    Med Decis Making 25:301-7. 2005
  9. ncbi request reprint Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?
    John F Forbes
    Department of Surgical Oncology, University of Newcastle, NSW, Australia
    Breast Cancer Res Treat 75:S37-44; discussion S57-9. 2002
  10. ncbi request reprint Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005

Detail Information

Publications15

  1. ncbi request reprint Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables
    Peter M Ravdin
    Division of Medical Oncology, University of Texas Health Sciences Center at San Antonio, USA
    Lung Cancer 52:207-12. 2006
    ....
  2. doi request reprint Hormone replacement therapy and the increase in the incidence of invasive lobular cancer
    Peter M Ravdin
    University of Texas Health Sciences Center, San Antonio, TX, USA
    Breast Dis 30:3-8. 2008
    ....
  3. ncbi request reprint A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen
    Peter M Ravdin
    Division of Oncology, University of Texas Health Sciences Center, San Antonio, USA
    Clin Breast Cancer 5:313-6. 2004
    ..The decision tool supplies needed estimates of initial risk and allows adjustment for competing mortality. Uncertainties involved in making these estimates are also discussed...
  4. ncbi request reprint Managing the risk of osteoporosis in women with a history of early breast cancer
    Peter M Ravdin
    University of Texas Health Science Center San Antonio, Texas 78259 2307, USA
    Oncology (Williston Park) 18:1385-90, 1393; discussion 1394. 2004
    ....
  5. doi request reprint The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention
    Peter M Ravdin
    University of Texas Health Sciences Center at San Antonio, 78229, USA
    Cancer Prev Res (Phila) 3:686-8. 2010
    ....
  6. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
    ..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features...
  7. ncbi request reprint A decision aid to assist in adjuvant therapy choices for breast cancer
    Laura A Siminoff
    Case Western Reserve University, Cleveland, OH 44106 4976, USA
    Psychooncology 15:1001-13. 2006
    ..This study was a group randomized controlled trial of a novel decision aid to help patients with breast cancer make adjuvant therapy (AT) decisions...
  8. ncbi request reprint Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information
    Pamela B Peele
    Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA
    Med Decis Making 25:301-7. 2005
    ..The authors examined the impact of a patient-specific decision aid on women's decisions about adjuvant therapy for breast cancer...
  9. ncbi request reprint Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?
    John F Forbes
    Department of Surgical Oncology, University of Newcastle, NSW, Australia
    Breast Cancer Res Treat 75:S37-44; discussion S57-9. 2002
    ....
  10. ncbi request reprint Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005
    ....
  11. ncbi request reprint The decrease in breast-cancer incidence in 2003 in the United States
    Peter M Ravdin
    Department of Biostatistics, M D Anderson Cancer Center, Houston, USA
    N Engl J Med 356:1670-4. 2007
    ..The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded...
  12. ncbi request reprint Breast cancer trends: a marriage between clinical trial evidence and epidemiology
    Donald A Berry
    J Natl Cancer Inst 99:1139-41. 2007
  13. doi request reprint Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer
    Samuel J Wang
    Department of Radiation Medicine, KPV4, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    J Clin Oncol 26:2112-7. 2008
    ..The purpose of this study was to construct a survival prediction model to enable individualized predictions of the net survival benefit of adjuvant RT for gallbladder cancer patients based on specific tumor and patient characteristics...
  14. ncbi request reprint Population-based validation of the prognostic model ADJUVANT! for early breast cancer
    Ivo A Olivotto
    Breast Cancer Outcomes Unit, Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada
    J Clin Oncol 23:2716-25. 2005
    ..Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated...
  15. ncbi request reprint A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642 0001, USA
    Breast Cancer Res Treat 85:143-50. 2004
    ..To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial...